← Return to all swing-trade opportunities
ONC — Oversold Bullish Reversal
Status: Invalidated
Scanner score: 35.0/100
Why this was flagged
ONC was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 35.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest stored daily low of 336.9500 reached or fell below stop loss 341.2080.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The scanner looked at BeiGene Ltd, which has the symbol ONC. It found a pattern called an "Oversold Bullish Reversal." This means the stock price had fallen quickly, similar to how a ball stretches when you pull it back before it snaps forward. The scanner checked the market activity and saw that trading volume was high, meaning many people were trading that day. Also, a measuring tool called the RSI showed the stock was very low, which often happens before a price jump. The scanner gave this idea a score of 35 out of 100. This is a moderate score, not a perfect one.
What the price plan means
The plan started when the stock was around $341.80. The scanner suggested watching a small range up to $344.09. The plan aimed for two small goals: first to $342.98, and second to $343.57. These targets were very close to the starting price. This shows the plan expected a quick, short move. The plan included a safety net, or "stop loss," set just slightly below the start. This is a strict rule that says, "If the price drops below this number, the idea is wrong."
What could make the idea fail
This plan has already failed. The status is marked as "invalidated." Recent data shows the stock dropped to $336.95. This is lower than the safety net price of $341.20. Because the price fell past this limit, the scanner’s theory was proven wrong for this time. The strict safety rule worked as intended to cut off the loss early.
Important reminder
Technical screens like this are just math tools. They look at past charts to guess the future. They do not guarantee anything will happen. A score of 35 is not high, and the plan is now closed. Always check the latest numbers yourself. Never risk money you cannot afford to lose. This text explains the logic, not financial advice.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Positive (Moderate confidence)
BeiGene reported a substantial increase in H1 2026 net profit, rising by 627% to 3.27 billion yuan. This performance was primarily driven by robust global sales of Zanubrutinib, which reached 16.13 billion yuan. The company also experienced increased revenue from Amgen-authorized products and tislelizumab, alongside an expansion in gross margin and improved operating efficiency. Additionally, BeiGene received FDA approval for a new indication for tislelizumab and raised its full-year revenue guidance, signaling strengthened confidence in Zanubrutinib's long-term growth potential.
Potentially supportive context
- H1 2026 net profit surged by 627% to 3.27 billion yuan.
- Global sales of core product Zanubrutinib reached 16.13 billion yuan.
- FDA approval received for a new indication for tislelizumab.
Risks and caution items
- The technical score of 35 is relatively low, suggesting potential weakness in broader technical indicators.
- Recent reliance on strong sales growth from a single core product may pose concentration risk.
- Limited coverage with only one article reduces the scope of external verification.
Latest reviewed article: Aug 30, 2026 8:24 pm
Recent related articles
BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven by strong global sales of its core product, Zanubrutinib, which reached 16.13 billion yuan. The company also saw increased revenue from Amgen-authorized products…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Current volume is at least 1.25x the 20-day average volume.
- RSI is near oversold territory with bullish candle confirmation.